Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Taylor, Lynn E ^a   Swan, Tracy ^b   Matthews, Gail V ^c,d  

^a BROWN UNIVERSITY   (United States)

^b Treatment Action Group   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

Direct acting antivirals (DAAs); HCV HIV coinfection; Hepatitis C virus; HIV; People who inject drugs (PWID)

Indexed keywords

ABACAVIR; ACTIVE ANTIRETROVIRAL; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INTERFERON; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; STAVUDINE; TELAPREVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADDICTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL STUDY; COMORBIDITY; COUNSELING; DISEASE COURSE; DRUG USE; EPIDEMIC; GENOTYPE; HEALTH CARE ACCESS; HEALTH SERVICE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERBILIRUBINEMIA; INCIDENCE; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; MORBIDITY; MORTALITY; OPIATE SUBSTITUTION TREATMENT; OPPORTUNISTIC INFECTION; PERCEPTION; POLYPHARMACY; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; RISK REDUCTION; SEXUAL TRANSMISSION; SURVIVAL; TOXIC HEPATITIS; TREATMENT OUTCOME; VIRAL CLEARANCE;

DIRECT-ACTING ANTIVIRALS (DAAS); HCV/HIV COINFECTION; HEPATITIS C VIRUS; HIV; PEOPLE WHO INJECT DRUGS (PWID);

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84880998138     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit326     Document Type: Article

References (58)

1. Stockman JK, Strathdee SA. HIV among people who use drugs: a global perspective of populations at risk. J Acquir Immune Defic Syndr 2010; 55:S17-22.
2. Walsh N, Maher L. HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment. Curr Opin HIVAIDS 2012; 7: 339-44.
3. Bottieau E, Apers L, Esbroeck MV, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill 2010; 15:19673.
4. van der Helm JJ, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011; 25: 1083-91.
5. Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012; 55: 1408-16.
6. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis 2013; 56: 1480-7.
7. Jin F, Prestage GP, Matthews G, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010; 86: 25-8.
8. Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005; 41: 395-402.
9. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012; 55(suppl 1):S33-42.
10. Lambers FA, Brinkman K, Schinkel J, et al. Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS 2011; 25: 1333-6.
11. McGovern BH, Nagami EH, Birch CE, et al. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis 2009; 200: 877-81.
12. Piroth L, Larsen C, Binquet C, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010; 52: 1915-21.
13. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25: 399-409.
14. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liverrelated mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57: 743-51.
15. van der Helm J, Geskus R, Sabin C, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013; 144:751-60.e2.
16. Holmberg SD, Ly KN, Xing J, Klevens M, Jiles R, Ward JW. The growing burden of mortality associated with viral hepatitis in the United States, 1999-2007. In: 62th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, California, 2011.
17. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
18. de Ledinghen V, Barreiro P, Foucher J, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat 2008; 15: 427-33.
19. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.
20. Kim AY, Chung RT. Coinfection with HIV-1 and HCV - a one-two punch. Gastroenterology 2009; 137: 795-814.
21. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010; 52: 612-22.
22. Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, Jabs DA. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis 2012; 55: 137-44.
23. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-8.
24. Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis 2007; 45(suppl 4):S248-54.
25. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
26. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
27. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 13 February 2013.
28. McGowan CC, Weinstein DD, Samenow CP, et al. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One 2011; 6:e18462.
29. Mehta SH, Kirk GD, Astemborski J, Galai N, Celentano DD. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008. Clin Infect Dis 2010; 50: 1664-71.
30. Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis 2010; 10: 464-9.
31. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-91.
32. Re VL. Increased risk of hepatic decompensation and hepatocellular carcinoma in HIV/HCV-co-infected patients compared to HCVmono- infected patients despite combination antiretroviral therapy. In: 19th International AIDS Conference, Washington, DC, 2012.
33. Ingiliz P, Valantin MA, Preziosi P, et al. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis. J Hepatol 2012; 56: 49-54.
34. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196: 670-6.
35. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056-63.
36. Macias J, del Valle J, Rivero A, et al. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother 2010; 65: 2204-11.
37. Mira JA, Rivero-Juarez A, Lopez-Cortes LF, et al. Benefits from sustained virological response to pegylated interferon plus ribavirin in HIV/HCVcoinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56: 1646-53.
38. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
39. European AIDS Clinical Society. Guidelines, version 6.1. Available at: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EacsGuidelines-v6.1-2edition.pdf. Accessed 8 February 2013.
40. Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis 2013; 13:9.
41. Jafferbhoy H, Miller MH, Dunbar JK, Tait J, McLeod S, Dillon JF. Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection. J Viral Hepat 2012; 19: 112-9.
42. Neukam K, Mira JA, Gilabert I, et al. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Eur J Clin Microbiol Infect Dis 2012; 31: 1225-32.
43. Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol 2010; 22: 1050-7.
44. Litwin AH, Harris KA Jr, Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37: 32-40.
45. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22: 1519-25.
46. Seal KH, Currie SL, Shen H, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? J Clin Gastroenterol 2007; 41: 199-205.
47. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20: 2361-9.
48. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29: 159-65.
49. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40(suppl 5):S325-9.
50. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98: 2281-8.
51. Sulkowski MS, Sherman KE, Soriano V, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR24 final study results. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, 2012.
52. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results [SVR12 data in oral presentation]. In: 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, 2012.
53. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-73.
54. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000; 14: 151-5.
55. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/ naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011; 56(suppl 1): S22-32.
56. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188-94.
57. Rodriguez-Torres M, Gonzalez M, Rossi S, et al. HIV/HCV coinfected and HCV monoinfected patients have similar early HCV viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir (SOF). In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 9-12 September 2012.
58. Kirby B, Mathias A, Rossi S, Moyer C, Shen G, Brian P. Kearney Gilead Sciences, Inc. GS-7977 & HIVARTs PK - no clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, 9-13 November 2012.